Quick Information
- Category:
- Healthcare
- Pricing:
- Contact Sales
- Platforms:
- Cloud, Lab automation
- Free Plan:
- No
- Last Verified:
- October 2026
What Is Recursion?
Recursion is a clinical-stage TechBio company based in Salt Lake City that uses an AI-enabled drug discovery platform, the Recursion Operating System, to decode biology and design new medicines. It trades on Nasdaq as RXRX. In 2024 it agreed to merge with UK-based Exscientia in a deal worth about $700 million in stock, which closed in November 2024 and added more than 20 programs to the portfolio and raised its milestone opportunity to over $20 billion.
For 2026 management said it was focused on five clinical programs and expected early Phase 1 data from several candidates, including REC-1245 and REC-7735. It also planned FDA engagement in the first half of 2026 on a registration path for REC-4881 in familial adenomatous polyposis, which has Fast Track status, and it advances REC-994 in cerebral cavernous malformation. Financially, first quarter 2026 revenue was about $6.5 million against a net loss near $117.5 million, with cash runway extended into early 2028. Analysts point out the company has no approved drug and that AI-discovered compounds have not yet produced a blockbuster. Most of these details come from secondary sources, so check Recursion's own filings.
Recursion suits investors, pharma partners and researchers tracking AI drug discovery. Compare Insilico Medicine, Isomorphic Labs and Schrödinger. Browse the Healthcare tools directory for more.
What Can You Use Recursion For?
Drug discovery
Uses AI and automation to find and design medicines.
Clinical development
Advances five clinical programs in 2026.
Pharma collaboration
Milestone-based partnerships.
Recursion Features
- Recursion Operating System — Full-stack platform for discovery and development.
- Exscientia programs — More than 20 programs added through the merger.
- Clinical pipeline — Includes REC-4881 and REC-994.
- Public company — Listed on Nasdaq as RXRX.
Who Is Recursion For?
- Pharma partners — Collaborate on AI-discovered programs.
- Investors and researchers — Follow a flagship TechBio company.
Recursion Pros & Limitations
What We Like
- Large pipeline after the Exscientia merger
- Public reporting
- Cash runway into early 2028
Limitations
- No approved drug yet
- Large net losses against small revenue
- Details come mostly from secondary sources
Recursion Pricing
| Plan | Price | Main Features |
|---|---|---|
| Partnerships | Custom | Collaborations on drug discovery programs |
Pricing was last verified October 2026. Check the official website for the latest pricing.
AI Listing Jungle Ranking
- Global Rank:
- #271
- Overall Score:
- 72.5/100
- Monthly Users:
- –
- Rank Change:
- ▼ 79
This ranking reflects AI Listing Jungle's own independent scoring methodology and is not an endorsement by Recursion or its company. How Our Rankings Work
Frequently Asked Questions
What is Recursion?
A clinical-stage TechBio company using AI and automation for drug discovery, listed as RXRX.
Did Recursion merge with Exscientia?
Yes, a roughly $700M all-stock deal closed in November 2024.
Does Recursion have approved drugs?
No approved drug was reported.
What is its cash runway?
Extended into early 2028, per management.
Our Take
Recursion has scale and a real pipeline, but still has to prove AI-discovered drugs can win approval.
Watch the Phase 1 and FDA registration updates rather than the marketing.
Recursion Alternatives
Recursion Comparisons
Ready to try Recursion?
Visit the official website to get started.
Visit Official WebsiteAI Listing Jungle is an independent AI tools directory. Product names, logos, and trademarks belong to their respective owners.